A Study on the Bioequivalence of Perindopril Tert-butylamine Tablets Taken on an Empty Stomach in Healthy Subjects

NCT04556058 | Completed Phase 1

• 1 other identifier: SZYQ-BE-2018-004
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

In order to evaluate the bioequivalence of the test preparations and reference preparations of perindopril tert-butylamine tablets after meal and their safety in Chinese adult healthy subjects.

Conditions

Healthy

Keywords

perindopril tert-butylamine; Bioequivalence study; fasting

Outcome Measures

Primary Outcomes (2)

• Maximum drug concentration (Cmax) of Perindopril

  Before administration (within 2 hours) and 10 minutes to 72 hours after administration

• Area under the plasma concentration versus time curve （AUC0-∞、AUC0-t）of Perindopril

  Before administration (within 2 hours) and 10 minutes to 72 hours after administration

Secondary Outcomes (4)

• Time to reach maximum plasma concentration(Tmax) of Perindopril and Perindoprilat

  Before administration (within 2 hours) and 10 minutes to 72 hours after administration

• Terminal elimination half-life（t1/2 ）of Perindopril and Perindoprilat

  Before administration (within 2 hours) and 10 minutes to 72 hours after administration

• Maximum drug concentration (Cmax) of Perindoprilat

  fore administration (within 2 hours) and 10 minutes to 72 hours after administration

• Area under the plasma concentration versus time curve （AUC0-∞、AUC0-t）of Perindoprilat

  Before administration (within 2 hours) and 10 minutes to 72 hours after administration

Other Outcomes (1)

• Adverse event rate

  from the screening to 18 days post-dose

Study Arms (2)

Perindopril tert-Butylamine tablets （ Produced by Haisco）

EXPERIMENTAL

The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.

Drug: Perindopril tert-Butylamine tablets （ Produced by Haisco）

Perindopril tert-Butylamine tablets（ACERTIL®）

ACTIVE COMPARATOR

The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.

Drug: Perindopril tert-Butylamine tablets（ACERTIL®）

Interventions

Perindopril tert-Butylamine tablets （ Produced by Haisco） DRUG

The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.

Perindopril tert-Butylamine tablets （ Produced by Haisco）

Perindopril tert-Butylamine tablets（ACERTIL®） DRUG

The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.

Perindopril tert-Butylamine tablets（ACERTIL®）

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy volunteers between the ages of 18 and 50 (including cut-off values), both male and female;
• Male weight ≥50kg, female weight ≥45kg, and body mass index (BMI) 19-26kg/m2 (including cut-off values);
• Sign the informed consent form voluntarily;
• Be able to maintain good communication with researchers and comply with various requirements of clinical trials.

You may not qualify if:

• People who is addicted to alcohol, tobacco,(drink 14 units of alcohol per week within the first month of enrollment: 1 unit = 285 ml of beer, or 25 ml of spirits, or 1 glass of wine; average daily smoking in the 3 months before screening ≥5) and/or those who cannot ban smoking and alcohol during the trial; or those who have a positive result alcohol breath trial;
• Use any prescription drugs (such as antihypertensive drugs) within 4 weeks before screening, or use any over-the-counter drugs (vitamins, Chinese herbal tonics) within 2 weeks before screening, or take foods that affect metabolism within 2 weeks before screening, such as grapefruit or a drink containing grapefruit (acetaminophen can be used, but it must be recorded in the concomitant medication of CRF); or the subject refused to stop using foods that affect CYP1A2 during the trial, such as coffee, tea, cola, chocolate, etc.
• Those who have used any drugs with a long half-life that may affect this study, or have participated in any drug clinical trials as subjects in the past 3 months;
• Blood donation or blood loss ≥ 400mL within 8 weeks before the first administration;
• People with a history of food or drug allergy, or allergies;
• Any clinically significant physical examination, vital signs, electrocardiogram or clinical laboratory measurement abnormalities during screening;
• Suffer from blood system, circulatory system, digestive system, urinary system, respiratory system, nervous system, immune system, endocrine system, mental abnormality, metabolic abnormality or any other chronic or serious disease history or existing disease that may affect the results of the study Those with the aforementioned systemic diseases;
• Human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or Treponema pallidum antibody (TPPA) has a positive result;
• Those who have a history of drug abuse or drug dependence;
• People who have a history of fainting needles and blood, or who cannot tolerate venipuncture blood sampling and known serious bleeding tendency;
• Patients with resting systolic blood pressure ≤90 mmHg, ≥140mmHg, or diastolic blood pressure ≤60 mmHg, ≥90mmHg, or pulse (HR) ≤50bpm, ≥100bpm;
• Pregnant or lactating women, or female subjects whose pregnancy test results are positive; subjects (or their partners) have birth plans or sperm and egg donors during the entire trial period and within 3 months after the end of the study; trial Those who are unwilling to take one or more physical contraceptive measures during the period and within 3 months after the end of the study;
• Patients with congenital galactosemia, glucose and galactose malabsorption syndrome, or lack of lactase;

Sponsors & Collaborators

• Sichuan Haisco Pharmaceutical Group Co., Ltd: lead

Study Sites (1)

General Hospital of the northern theater of the Chinese people's Liberation Army

Shenyang, Liaoning, China

Location

MeSH Terms

Conditions

Fasting

Interventions

perindopril tert-butylamine

Condition Hierarchy (Ancestors)

Feeding Behavior; Behavior

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 25, 2020
• First Posted: September 21, 2020
• Study Start: November 29, 2018
• Primary Completion: March 8, 2019
• Study Completion: March 15, 2019
• Last Updated: September 21, 2020

Record last verified: 2020-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)